• 1
    Castagnaro M., Amedeo S., Bertolotto A., et al. Morphological and biochemical investigations of mitral valve endocardiosis in pigs. Res Vet Sci 1997;62: 121125.
  • 2
    Seki Y., Machida N., Arimura T., et al. Transmural myocardial infarction caused by thromboembolism associated with mitral insufficiency in a dog. J Vet Med Sci 1998;60: 741743.
  • 3
    Falk T., Jonsson L.. Ischaemic heart disease in the dog: A review of 65 cases. J Small Anim Pract 2000;41: 97103.
  • 4
    Whitney JC. Cardiovascular pathology. J Small Anim Pract 1967;8: 459465.
  • 5
    Pedersen HD. Mitral Valve Prolapse in the Dog. Pathogenesis, Pathophysiology, Diagnosis and Comparative Aspects of Early Myxomatous Mitral Valve Disease. Copenhagen , Denmark : Royal Veterinary and Agricultural University; 2000. Thesis.
  • 6
    Pedersen HD, Haggstrom J.. Mitral valve prolapse in the dog: A model of mitral valve prolapse in man. Cardiovasc Res 2000;47: 234243.
  • 7
    Pedersen HD, Kristensen HO, Lorentzen KA, et al. Mitral valve prolapse in 3-year-old healthy Cavalier King Charles Spaniels. An echocardiographic study. Can J Vet Res 1995;59: 294298.
  • 8
    Olsen LH, Fredholm M., Pedersen HD. Epidemiology and inheritance of mitral valve prolapse in Dachshunds. J Vet Intern Med 1999;13: 448456.
  • 9
    Mow T., Pedersen HD. Increased endothelin receptor density in myxomatous canine mitral valve leaflets. J Cardiovasc Pharmacol 1999;34: 254260.
  • 10
    Corcoran BM, Black A., Anderson H., et al. Identification of surface morphologic changes in the mitral valve leaflets and chordae tendineae of dogs with myxomatous degeneration. Am J Vet Res 2004;65: 198206.
  • 11
    Olsen LH, Mortensen K., Martinussen T., et al. Increased NADPH-diaphorase activity in canine myxomatous mitral valve leaflets. J Comp Pathol 2003;129: 120130.
  • 12
    Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107: 363369.
  • 13
    Dvorakova A., Poledne R.. High-sensitivity C-reactive protein—New parameter in cardiovascular risk assessment. Vnitr Lek 2004;50: 852857.
  • 14
    Edward TH, Yeh MD, Willerson JT. Coming of age of C-reactive protein: Using inflammation markers in cardiology. Circulation 2003;107: 370372.
  • 15
    Mold C., Gewurz H., Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999;42: 2330.
  • 16
    Pasceri V., Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2002;105: 21652168.
  • 17
    Nakajima T., Schulte S., Warrington KJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002;105: 570575.
  • 18
    Nakagomi A., Freedman SB, Geczy CL. Interferongamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment. Circulation 2000;101: 17851791.
  • 19
    Blaschke F., Bruemmer D., Yin F., et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004;110: 579587.
  • 20
    Venugopal SK, Devaraj S., Jialal I.. C-Reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003;108: 16761678.
  • 21
    Verma S., Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105: 18901896.
  • 22
    Verma S., Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106: 913919.
  • 23
    Vojtic I., Weingerl S., Kebric F.. The use of C-reactive protein for differentiating physiological and pathological conditions in dogs. Veterinarske Novice 2000;26: 159165.
  • 24
    McGrotty YL, Knottenbelt CM, Ramsey IK, et al. Evaluation of a rapid assay for canine C-reactive protein. Vet Rec Br Vet Assoc 2004;154: 175176.
  • 25
    Holm JL, Rozanski EA, Freeman LM, et al. C-reactive protein concentrations in canine acute pancreatitis. J Vet Emerg Crit Care 2004;14: 183186.
  • 26
    Burton SA, Honor DJ, Mackenzie AL, et al. C-Reactive protein concentrations in dogs with inflammatory leukograms. Am J Vet Res 1994;55: 613618.
  • 27
    Yamamoto S., Shida T., Miyaji H., et al. Changes in serum C-reactive protein levels in dogs with various disorders and surgical traumas. Vet Res Commun 1993;17: 8593.
  • 28
    Fujitani Y., Trifilieff A., Tsuyuki S., et al. Endothelin receptor antagonists inhibit antigen-induced lung inflammation in mice. Am J Respir Crit Care Med 1997;155: 18901894.
  • 29
    Muller DN, Fiebeler A., Park JK, et al. Angiotensin II and endothelin induce inflammation and thereby promote hypertension-induced end-organ damage. Clin Nephrol 2003;60(Suppl 1):212.
  • 30
    Palmer RMJ, Ferridge AG, Moncada S.. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1988;333: 664666.
  • 31
    Moncada S., Higgs A.. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329: 20022012.
  • 32
    de Laforcade AM, Freeman LM, Rush JE. Serum nitrate and nitrite in dogs with spontaneous cardiac disease. J Vet Intern Med 2003;17: 315318.
  • 33
    Pedersen HD, Schutt T., Sondergaard R., et al. Decreased plasma concentration of nitric oxide metabolites in dogs with untreated mitral regurgitation. J Vet Intern Med 2003;17: 178184.
  • 34
    Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341: 142147.
  • 35
    Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110: 12911295.
  • 36
    Mohler ER III, Gannon F., Reynolds C., et al. Bone formation and inflammation in cardiac valves. Circulation 2001;103: 15221528.
  • 37
    O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of “degenerative” valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16: 523532.
  • 38
    Galante A., Pietroiusti A., Vellini M., et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001;38: 10781082.
  • 39
    O'Driscoll G., Green D., Taylor RR. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95: 11261131.
  • 40
    Aikawa M., Rabkin E., Okada Y., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma. Circulation 1998;97: 24332444.
  • 41
    Bustos C., Hernandez-Presa MA, Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduced neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32: 20572064.
  • 42
    Hernandez-Presa MA, Martin-Ventura JL, Ortego M., et al. Atorvastatin reduces the expression of cyclo-oxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002;160: 4958.
  • 43
    Ridker PM, Rifai N., Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98: 839844.
  • 44
    Ridker PM, Rifai N., Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100: 230235.
  • 45
    Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104: 22052209.
  • 46
    Pate GE, Tahir MN, Murphy RT, et al. Anti-inflammatory effects of statins in patients with aortic stenosis. J Cardiovasc Pharmacol Ther 2003;8: 201206.
  • 47
    Williams MJA, Williams SM, Milne BJ, et al. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes 2004;28: 9981003.